Casimersen - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for casimersen and what is the scope of patent protection?
Casimersen
is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Casimersen has seventy-eight patent family members in twenty-four countries.
One supplier is listed for this compound.
Summary for casimersen
| International Patents: | 78 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 3 |
| What excipients (inactive ingredients) are in casimersen? | casimersen excipients list |
| DailyMed Link: | casimersen at DailyMed |
Recent Clinical Trials for casimersen
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Kevin Flanigan | Phase 2 |
| Sarepta Therapeutics, Inc. | Phase 2 |
| Sarepta Therapeutics, Inc. | Phase 3 |
Pharmacology for casimersen
| Drug Class | Antisense Oligonucleotide |
| Physiological Effect | Increased Protein Synthesis |
US Patents and Regulatory Information for casimersen
Expired US Patents for casimersen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | See Plans and Pricing | See Plans and Pricing |
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for casimersen
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2693459 | See Plans and Pricing | |
| South Korea | 20210041130 | See Plans and Pricing | |
| Serbia | 58079 | See Plans and Pricing | |
| New Zealand | 626359 | Antisense molecules and methods for treating pathologies | See Plans and Pricing |
| Spain | 2564185 | See Plans and Pricing | |
| Hong Kong | 1245325 | 用於誘導外顯子跳躍的反義寡核苷酸及其使用方法 (ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
